Laman UtamaPRE • NASDAQ
Prenetics Global Ltd
$5.88
14 Jan, 4:09:46 PG GMT-5 · USD · NASDAQ · Penafian
SahamSekuriti tersenarai AS
Tutup sebelumnya
$5.44
Julat hari
$5.27 - $5.89
Julat tahun
$2.85 - $7.84
Permodalan pasaran
71.84J USD
Bilangan Purata
11.94K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD)Sep 2024Perubahan T/T
Hasil
7.78J59.86%
Perbelanjaan pengendalian
15.76J2.99%
Pendapatan bersih
-10.67J21.36%
Margin untung bersih
-137.2150.80%
Pendapatan bagi setiap syer
EBITDA
-10.71J14.43%
Kadar cukai berkesan
0.62%
Jumlah aset
Jumlah liabiliti
(USD)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
48.69J-45.29%
Jumlah aset
235.77J-14.71%
Jumlah liabiliti
55.67J16.88%
Jumlah ekuiti
180.10J
Syer tertunggak
12.72J
Harga kepada buku
0.39
Pulangan pada aset
-12.59%
Pulangan pada modal
-15.54%
Perubahan bersih dalam tunai
(USD)Sep 2024Perubahan T/T
Pendapatan bersih
-10.67J21.36%
Tunai daripada operasi
Tunai daripada pelaburan
Tunai daripada pembiayaan
Perubahan bersih dalam tunai
Aliran tunai bebas
Perihal
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Diasaskan
2014
Tapak web
Pekerja
322
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama